Skip to main content

01.09.2009 | Glaucoma | Ausgabe 9/2009

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2009

Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: A short-term study by pattern electroretinogram

Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 9/2009
Benedetto Falsini, Dario Marangoni, Tommaso Salgarello, Giovanna Stifano, Lucrezia Montrone, Salvatore Di Landro, Laura Guccione, Emilio Balestrazzi, Alberto Colotto
Wichtige Hinweise
Drs Falsini and Marangoni contributed equally to this article



Epigallocatechin-gallate (EGCG) is a powerful antioxidant with suggested neuroprotective action. The aim of this study was to evaluate the effect of short-term supplementation of EGCG on inner retinal function in ocular hypertension (OHT) and open-angle glaucoma (OAG).


Eighteen OHT and 18 OAG patients (perimetric mean deviation: >−10 dB) were randomly assigned to assume oral placebo or EGCG over a 3-month period in a randomized, placebo-controlled, double-blind, cross-over design clinical trial ( identifier: NCT00476138). Pattern-evoked electroretinograms (PERGs) to 1.6 cycles/degree square-wave gratings, counterphased at 16 reversals/second, and standard automated perimetry (Humphrey 30–2) were assessed at the study entry (baseline), and after 3 months of placebo or EGCG.


After EGCG, PERGs of OAG, but not OHT patients were increased in amplitude, compared either to baseline values (mean amplitude change: 0.06 log μV, p < 0.05) or to PERG amplitude values found in the same patients after placebo administration (mean change: −0.02 log μV, p not significant; difference between EGCG and placebo: 0.08 log μV, p < 0.05). In both OHT and OAG patients, standard automated perimetry did not show significant changes after either EGCG or placebo. In individual OAG patients, the magnitude of PERG amplitude increment after EGCG was inversely related (r = −0.8, p < 0.01) to corresponding baseline amplitudes.


Although this study cannot provide evidence for long-term benefit of EGCG supplementation in OAG, and the observed effect is small, the results suggest that EGCG might favourably influence inner retinal function in eyes with early to moderately advanced glaucomatous damage.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Nicht verpassen: e.Med bis 13. März 2019 100€ günstiger im ersten Jahr!

Über diesen Artikel

Weitere Artikel der Ausgabe 9/2009

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2009 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde